Otologic Pharmaceutics, an Oklahoma City-based biopharmaceutical company focused on treating hearing disorders, raised $4.1m in Series A funding.
Accele Venture Partners, the investing arm of Accele Biopharma and i2E led the round with participation from the Oklahoma Life Science Fund. In conjunction with the financing, Accele Biopharma’s Chairman and CEO Clayton I. Duncan has been named CEO of Otologic Pharmaceutics, replacing David Karlman.
The company intends to use the funds to advance the development of its lead product candidate, NHPN-1010.
Otologic Pharmaceutics is a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders. Its lead product is HPN1010, an oral treatment for Acute Hearing Loss, which is scheduled to enter clinical trials in 2014.
FinSMEs
04/04/2014